biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Some Reality Therapy

<< Previous

Bullboard Posts

Next >>

Comment by InitiumMMXXIIIon Nov 17, 2023 3:42pm

136 Views

Post# 35741831

RE:RE:RE:RE:RE:RE:RE:RE:Some Reality Therapy

Maybe you ought to go look at what copywriters and technical writers do, TT. About 99% of the work we do is not publicly attributed. It was years before I publicly revealed that I was wring Bioasis' press releases. I've had clients where my contract forbade me from publicly revealing that I was writing for them. That's a common clause in nondisclosure agreements. Obviously, you don't know very much about this stuff, TT.

Frankly, I never want to be associated with public companies again. I've had that well and truly beaten out of me. Most of the work for writers is outside of that area anyway.

jd

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario